SER-155

Microbiome therapeutic

On holdsponsor decision

Evidence outlook · program status

On hold, for financing reasons

After advancing startup activities for the Phase 2 study, the company paused additional investment in the program as part of cost reduction actions while continuing to seek funding. Company Form 10-Q; approved in the freshness review queue. The trials below are the program's evidence history; no evidence signal is assigned while development is paused.

Source for the program status

How the evidence outlook works ↗

All registered studies

Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase.

Phase 1 (2)
Bacterial Infections in Allogeneic Stem Cell Transplant
Other / comorbidity
NCT06801067 · Memorial Sloan Kettering Cancer Center
2025-01-24 – 2027-01-24 · Diarrhea, Enterocolitis
What this study did

Competitive landscape

No competitors sharing a mechanism or indication in the current universe.

Upcoming events

(1 total)

Development is on hold (source ↗). ClinicalTrials.gov still lists the estimated primary-completion dates below; they may not read out as listed.

2027 (1)
January 2027 (1)
Phase 1Diarrhea, EnterocolitisRecruitingProgramme on hold
Est. primary completion 2027-01-24 · NCT06801067 · CT.gov ↗
What to watch

See the full readout calendar ↗

Regulatory and conference events

(1)

Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.

Recent

8 July 2026Topline resultSER-155 topline results in irEC investigator-sponsored study